Peroxisome dysfunction disrupts metabolism of photoreceptor outer segments in human retinal pigment epithelium
Stem Cell Reports · 2026-11 · 103148
DOI: 10.1016/j.stemcr.2026.103148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cell Reports, 2026-11. Verfasst von Constantin Mouzaaber und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, AB, Canada. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Macular Degeneration Foundation, Foundation for the National Institutes of Health, Foundation Fighting Blindness.
Abstract (Originalsprache)
Retinal degeneration and blindness frequently develop in patients with peroxisomal disorders, yet mechanisms remain obscure. Peroxisomes are organelles that compartmentalize metabolic reactions including lipid catabolism and cellular detoxification. Here, we generated induced pluripotent stem cell-derived human retinal pigment epithelial cells (iRPEs) deficient in the essential peroxisomal proteins PEX1 and PEX6 to study the effects of peroxisome dysfunction in a disease-relevant cell type. Following a physiologically relevant photoreceptor outer segment (POS) challenge, PEX1-/- and PEX6-/- iRPEs demonstrated impaired polyunsaturated fatty acid retroconversion, lipid droplet accumulation, and reduced transepithelial electrical resistance. Additionally, PEX1-/- and PEX6-/- iRPEs exhibited a failure in the clearance of rhodopsin, the major protein in POS, which coincided with a broader defect in lysosomal function. These findings suggest that dysregulated POS metabolism in the retinal pigment epithelium is a potential mechanism driving retinal degeneration in patients with peroxisomal disorders and provide a basis for investigating lysosomal enhancement as a therapeutic strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, AB, Canada.
- Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
- Peroxisomal Diseases Laboratory, Kennedy Krieger Institute, Baltimore, MD, USA.
- Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.
- Flow Cytometry Core Facility, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
- Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, MD, USA; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Förderung
- American Macular Degeneration Foundation
- Foundation for the National Institutes of Health
- Foundation Fighting Blindness
Zitieren
APA
Mouzaaber, C., Feldman, C. B., Huguenin, S. M., Han, J. Y. S., Trombly, E., Zhang, Q., Rieger, A., Hojjat, H., Huynh, B. C., Misaghi, E., Radziwon, A., Fufa, T. D., Hufnagel, R. B., Miller, J. M. L., & Benson, M. D. (2026). Peroxisome dysfunction disrupts metabolism of photoreceptor outer segments in human retinal pigment epithelium. Stem Cell Reports, 103148. https://doi.org/10.1016/j.stemcr.2026.103148
Vancouver
Mouzaaber C, Feldman CB, Huguenin SM, Han JYS, Trombly E, Zhang Q, et al. Peroxisome dysfunction disrupts metabolism of photoreceptor outer segments in human retinal pigment epithelium. Stem Cell Reports. 2026:103148. doi:10.1016/j.stemcr.2026.103148
BibTeX
@article{Mouzaaber2026,
author = {Mouzaaber, Constantin and Feldman, Carly B and Huguenin, Suzette M and Han, John Y S and Trombly, Erin and Zhang, Qitao and Rieger, Aja and Hojjat, Hamed and Huynh, Brandon C and Misaghi, Ehsan and Radziwon, Alina and Fufa, Temesgen D and Hufnagel, Robert B and Miller, Jason M L and Benson, Matthew D},
title = {Peroxisome dysfunction disrupts metabolism of photoreceptor outer segments in human retinal pigment epithelium},
journal = {Stem Cell Reports},
year = {2026},
pages = {103148},
doi = {10.1016/j.stemcr.2026.103148}
}
EUVIMED